Voyager Therapeutics (VYGR) Change in Account Payables (2014 - 2026)

Voyager Therapeutics has disclosed Change in Account Payables across 13 years of filings, most recently posting -$2.3 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$2.3 million, down 68.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $89000.0 (up 101.8% YoY), and the FY2025 annual result was $1.0 million, down 57.48% from the prior year.
• Change in Account Payables came in at -$2.3 million for Q1 2026 at Voyager Therapeutics, down from $2.9 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.0 million in Q1 2024 to a low of -$5.0 million in Q2 2024.
• The 5-year median for Change in Account Payables is $312000.0 (2025), against an average of $126411.8.
• Across the five-year window, Change in Account Payables surged 6927.78% in 2022 and plunged 11427.78% in 2023, its largest moves.
• Voyager Therapeutics' Change in Account Payables stood at $1.2 million in 2022, then plunged by 235.56% to -$1.7 million in 2023, then jumped by 150.18% to $836000.0 in 2024, then soared by 246.53% to $2.9 million in 2025, then sank by 179.05% to -$2.3 million in 2026.
• The last three Change in Account Payables figures came in at -$2.3 million (Q1 2026), $2.9 million (Q4 2025), and $312000.0 (Q3 2025), per Business Quant data.